Publications

5674 Results

Somatic DNA mutations, mutational load (ML), and MSI status: association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 Alliance)

Authors
F Innocenti;FS Qu;T Zemla;D Niedzwiecki;X Qu;R Tam;SA Mahajan;R Goldberg;RJ Mayer;M Bertagnolli;H Hochster;C Blanke;A Venook;H Lenz;O Kabbarah
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 3504); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)

Authors
H Lenz;FS Ou;A Venook;H Hochster;D Niedzwiecki;R Goldberg;R Mayer;M Bertagnolli;C Blanke;T Zemla;X Qu;O Kabbarah;F Innocenti
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 3511); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral presentation
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Prospective pooled analysis of six phase III trials investigating duration of adjuvant oxaliplatin-based therapy (3 versus 6 months) for patients with stage III colon cancer: The IDEA(International Duration Evaluation of Adjuvant chemotherapy) collaboration

Authors
Q Shi;A Sobrero;A Shields;T Yoshino;J Taieb;I Souglakos;R Kerr;R Labianca;J Meyerhardt;F Bonnetain;T Watanabe;I Mpoukovinas;L Renfro;A Grothey;D Niedzwiecki;V Torri;T Andre;D Sargent
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr LBA1); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral, plenary
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702

American cancer society (ACS) nutrition and physical activity guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance)

Authors
E Van Blarigan;C Fuchs;D Niedzwiecki;X Ye;S Zhang;M Song;L Saltz;RJ Mayer;RB Mowat;R Whittom;A Hantel;A Benson;D Atienza;M Messino;H Kindler;A Venook;S Ogino;W Willett;EL Giovannucci;J Meyerhardt
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 10006); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral presentation
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
C89803

Nut consumption and survival in stage III colon cancer patients: results from CALGB 89803 (Alliance)

Authors
T Fadelu;D Niedzwiecki;S Zhang;X Ye;L Saltz;R Mayer;R Mowat;R Whittom;A Hantel;A Benson;D Atienza;M Messino;H Kindler;A Venook;S Ogino;K Ng;E Giovannucci;J Meyerhardt;Y Bao;C Fuchs
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 3517); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
C89803

Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance)

Authors
F Sinicrope;Q Shi;T Smyrk;R Goldberg;W Heying;E Chan;S Gill;M Kahlenberg;S Nair;A Shields;D Sargent;M Pollak;S Alberts
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 3516); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/N0147

Association of immune markers and immunoscore with survival of stage III colon cancer (CC) patients treated with adjuvant FOLFOX: NCCTG N0147 (Alliance)

Authors
F Sinicrope;Q Shi;F Hermitte;E Heying;E Chan;S Gill;R Goldberg;M Kahlenberg;S Nair;A Shields;D Sargent;J Galon;S Alberts
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 3579); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/N0147

Genetic correlates of therapeutic toxicities of stage III colon cancer patients treated with adjuvant FOLFOX+/-cetuximab (NCCTG N0147, Alliance)

Authors
P Newcomb;M Sun;X Hua;B Banbury;A Phipps;J Kocarnik;T Harrison;Q Shi;F Sinicrope;S Thidbodeau;E Chan;S Gill;R Goldberg;M Kahlenberg;S Nair;A Shields;U Peters;S Alberts;AT Chan
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 3604); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/N0147

Adjuvant androgen deprivation (AD) +mitoxantrone + prednisone (MP) in high risk prostate cancer (PC) patients post radical prostatectomy (RP): phase III intergroup trial S9921

Authors
M Hussain;C Tangen;IM Thompson;G Swanson;DP Wood;W Sakr;NA Dawson;NB Haas;TW Flaig;T Dorff;D Lin;ED Crawford;DI Quinn;N Vogelzang;LM Glode
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 5019); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion
Year
2017
Research Committee(s)
Genitourinary
Study Number(s)
S9921

Everolimus (EVE) exposure as a predictor of toxicity in renal cell cancer (RCC) patients (pts) in the adjuvant setting: results of pharmacokinetic analysis initial results for from SWOG S0931 (EVEREST), a phase III study (ClinicalTrials.gov Identifier:NCT01120249).

Authors
T Synold;M Plets;C Tangen;E Heath;G Palapattu;PC Mack;MN Stein;MV Meng;NJ Vogelzang;IM Thompson;C Ryan
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 4566); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Genitourinary
Study Number(s)
S0931